BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 19444414)

  • 1. [Role of TSH receptor autoantibodies for the diagnosis of Graves' disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. Recommendations of the Thyroid Section of the German Society of Endocrinology].
    Eckstein A; Mann K; Kahaly GJ; Grussendorf M; Reiners C; Feldkamp J; Quadbeck B; Bockisch A; Schott M
    Med Klin (Munich); 2009 May; 104(5):343-8. PubMed ID: 19444414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy.
    Eckstein A; Esser J; Mann K; Schott M
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():198-203. PubMed ID: 20467363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Graves Thyroidal and Extrathyroidal Disease: An Update.
    Kahaly GJ
    J Clin Endocrinol Metab; 2020 Dec; 105(12):3704-20. PubMed ID: 32929476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical review: Clinical utility of TSH receptor antibodies.
    Barbesino G; Tomer Y
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2247-55. PubMed ID: 23539719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the Relapse of Hyperthyroidism in Treated Graves' Disease with Orbitopathy by Serial Measurements of TSH-Receptor Autoantibodies.
    Stöhr M; Oeverhaus M; Lytton SD; Horstmann M; Zwanziger D; Möller L; Stark A; Führer-Sakel D; Bechrakis N; Berchner-Pfannschmidt U; Banga JP; Philipp S; Eckstein A
    Horm Metab Res; 2021 Apr; 53(4):235-244. PubMed ID: 33618407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graves' disease in clinical perspective.
    Ehlers M; Schott M; Allelein S
    Front Biosci (Landmark Ed); 2019 Jan; 24(1):35-47. PubMed ID: 30468646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
    De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
    Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Natural History of Subclinical Hyperthyroidism in Graves' Disease: The Rule of Thirds.
    Zhyzhneuskaya S; Addison C; Tsatlidis V; Weaver JU; Razvi S
    Thyroid; 2016 Jun; 26(6):765-9. PubMed ID: 27090092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative change of thyroid stimulating hormone receptor antibody level: possible marker for predicting recurrent hyperthyroidism in patients with Graves' disease after subtotal thyroidectomy.
    Sugino K; Mimura T; Ozaki O; Iwasaki H; Wada N; Matsumoto A; Ito K
    World J Surg; 1996 Sep; 20(7):801-6; discussion 806-7. PubMed ID: 8678954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyrotropin receptor autoantibody measurement following radiometabolic treatment of hyperthyroidism: comparison between different methods.
    Chiappori A; Villalta D; Bossert I; Ceresola EM; Lanaro D; Schiavo M; Bagnasco M; Pesce G
    J Endocrinol Invest; 2010 Mar; 33(3):197-201. PubMed ID: 20418655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
    Nicolì F; Lanzolla G; Mantuano M; Ionni I; Mazzi B; Leo M; Sframeli A; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
    J Endocrinol Invest; 2021 Mar; 44(3):581-585. PubMed ID: 32648002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional diagnostics for thyrotropin hormone receptor autoantibodies: bioassays prevail over binding assays.
    Lytton SD; Schluter A; Banga PJ
    Front Biosci (Landmark Ed); 2018 Jun; 23(11):2028-2043. PubMed ID: 29772543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication.
    Smith J; Brown RS
    Thyroid; 2007 Nov; 17(11):1103-7. PubMed ID: 17822376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
    Tun NN; Beckett G; Zammitt NN; Strachan MW; Seckl JR; Gibb FW
    Thyroid; 2016 Aug; 26(8):1004-9. PubMed ID: 27266892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of TSH-receptor antibody with the clinical and laboratory parameters in patients with newly diagnosed Graves' hyperthyroidism: experience from a tertiary referral center including a large number of patients with TSH-receptor antibody-negative patients with Graves' hyperthyroidism.
    Zuhur SS; Bilen O; Aggul H; Topcu B; Celikkol A; Elbuken G
    Endokrynol Pol; 2021; 72(1):14-21. PubMed ID: 32944926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disseminated thyroid autonomy or Graves' disease: reevaluation by a second generation TSH receptor antibody assay.
    Meller J; Jauho A; Hüfner M; Gratz S; Becker W
    Thyroid; 2000 Dec; 10(12):1073-9. PubMed ID: 11201852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.